Navigation Links
PRA Expert to Present at Pharmacovigilance Conference

RALEIGH, N.C., Nov. 22, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that the head of our Safety and Risk Management (SRM) group will speak at VIBPharma's 7th Annual Pharmacovigilance, Drug Safety and Risk Management conference being held in Brussels, Belgium from 22-23 November 2011.  PRA will also host an exhibit at booth #1, where additional SRM representatives will be available to discuss PRA's approach to pharmacovigilance.

On 22 November at 11:10AM CET, Dr. Sabine Richter, PRA's Vice President of SRM, will deliver a presentation titled, "Rationalising How Outsourcing Pharmacovigilance Activities Can Strengthen Your Regulatory Compliance and Immensely Increase Flexibility." Dr. Richter will discuss the key benefits of outsourcing drug safety services, review best practices for vendor management, and explore risk-sharing techniques that create effective cost reductions.

Dr. Richter has over 25 years of research experience in the pharmaceutical and clinical research industries as well as in academia. Since joining PRA's SRM team in 2004, she has delivered numerous projects for a variety of clients and led large, long-term safety programs involving as many as 50 countries on five continents. As the head of PRA's SRM group, Dr. Richter has developed robust procedures and quality control measures to ensure consistent high performance and regulatory compliance.

PRA's SRM group provides services throughout the entire product life cycle. The team includes over 100 experts available to clients for consultancy as well as routine and specialty pharmacovigilance services. Most of these staff members are healthcare professionals (nurses, pharmacists, physicians) or life scientists.  PRA's drug safety centers are based in our Mannheim, Germany; Swansea, UK; Charlottesville, VA (US); and Sao Paulo, Brazil offices.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit, email or call our Global Headquarters.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
2. The Foremost Expert on Morgellons Disease Highlights the Gravity of This Illness
3. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
4. Mind-Controlled Bionic Limbs Holding Promise, and the Demand is Growing say IEEE Experts
5. Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting
6. High voltage! Power experts pull out all the stops at international energy meeting
7. Expert Offers Solution to Hair Loss Concerns
8. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
9. Best Practices, LLC Showcases Its Expertise in Customer Relationship Management
10. M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches
11. Reagent Agent(SM) Transfection Cell Line Database From The Transfection Experts
Post Your Comments:
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
Breaking Biology Technology:
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
Breaking Biology News(10 mins):